Many patients dislike injections or struggle with long-term injectable treatments. A daily tablet could make obesity treatment more accessible and less intimidating for people uncomfortable with needles.
Cost may also play a significant role.
In the United States, orforglipron is already available and is reportedly much cheaper than many injectable GLP-1 drugs.
The lowest dose currently costs around $149 per month, compared with some injectable obesity medications that can exceed $1,000 per month without insurance coverage.
Former US President Donald Trump has recently announced efforts aimed at reducing the cost of popular weight-loss medications, as demand for GLP-1 drugs continues exploding worldwide.
It remains unclear how much orforglipron would cost in the United Kingdom because the medication has not yet officially launched there.
Meanwhile, rival pharmaceutical company Novo Nordisk — the maker of Wegovy and Ozempic — is also developing oral alternatives to injectable GLP-1 treatments.
READ MORE ON THE NEXT PAGE..
